LEADER 01000naa a22002652 4500
001 NLM232468338
003 DE-627
005 20231224093041.0
007 cr uuu---uuuuu
008 231224s2013 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2013.08.005  |2 doi 
028 5 2 |a pubmed24n0775.xml 
035 |a (DE-627)NLM232468338 
035 |a (NLM)24211713 
035 |a (PII)S1521-6616(13)00218-0 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Luu, Van Phi  |e verfasserin  |4 aut 
245 1 0 |a TSPAN33 is a novel marker of activated and malignant B cells 
264 1 |c 2013 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 30.12.2013 
500 |a Date Revised 21.10.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2013. 
520 |a We have identified Tspan33 as a gene encoding a transmembrane protein exhibiting a restricted expression pattern including expression in activated B cells. TSPAN33 is a member of the tetraspanin family. TSPAN33 is not expressed in resting B cells, but is strongly induced in primary human B cells following activation. Human 2E2 cells, a Burkitt's lymphoma-derived B cell model of activation and differentiation, also upregulate TSPAN33 upon activation. TSPAN33 is expressed in several lymphomas including Hodgkin's and Diffuse large B cell lymphoma. TSPAN33 is also expressed in some autoimmune diseases where B cells participate in the pathology, including rheumatoid arthritis patients, systemic lupus erythematosus (SLE), and in spleen B cells from MRL/Fas(lpr/lpr) mice (a mouse model of SLE). We conclude that TSPAN33 may be used as a diagnostic biomarker or as a target for therapeutic antibodies for treatment of certain B cell lymphomas or autoimmune diseases 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Research Support, U.S. Gov't, Non-P.H.S. 
650 4 |a B cell maturation antigen 
650 4 |a B cells 
650 4 |a BCMA 
650 4 |a BIGE 
650 4 |a BL 
650 4 |a Biomarker 
650 4 |a Burkitt's lymphoma 
650 4 |a DLBCL 
650 4 |a Diffuse large B cell lymphoma 
650 4 |a HL 
650 4 |a Hodgkin's lymphoma 
650 4 |a Lupus erythematosus 
650 4 |a Lymphoma 
650 4 |a NHL 
650 4 |a RA 
650 4 |a Rheumatoid arthritis 
650 4 |a SLE 
650 4 |a TSPAN33 
650 4 |a Tetraspanin 33 
650 4 |a body index of gene expression (database) 
650 4 |a non-Hodgkin's lymphoma 
650 4 |a rheumatoid arthritis 
650 4 |a systemic lupus erythematosus 
650 4 |a tetraspanin 33 
650 7 |a Biomarkers  |2 NLM 
650 7 |a Lipopolysaccharides  |2 NLM 
650 7 |a TSPAN33 protein, human  |2 NLM 
650 7 |a Tetraspanins  |2 NLM 
650 7 |a Tetradecanoylphorbol Acetate  |2 NLM 
650 7 |a NI40JAQ945  |2 NLM 
700 1 |a Hevezi, Peter  |e verfasserin  |4 aut 
700 1 |a Vences-Catalan, Felipe  |e verfasserin  |4 aut 
700 1 |a Maravillas-Montero, José Luis  |e verfasserin  |4 aut 
700 1 |a White, Clayton Alexander  |e verfasserin  |4 aut 
700 1 |a Casali, Paolo  |e verfasserin  |4 aut 
700 1 |a Llorente, Luis  |e verfasserin  |4 aut 
700 1 |a Jakez-Ocampo, Juan  |e verfasserin  |4 aut 
700 1 |a Lima, Guadalupe  |e verfasserin  |4 aut 
700 1 |a Vilches-Cisneros, Natalia  |e verfasserin  |4 aut 
700 1 |a Flores-Gutiérrez, Juan Pablo  |e verfasserin  |4 aut 
700 1 |a Santos-Argumedo, Leopoldo  |e verfasserin  |4 aut 
700 1 |a Zlotnik, Albert  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 149(2013), 3 vom: 28. Dez., Seite 388-99  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:149  |g year:2013  |g number:3  |g day:28  |g month:12  |g pages:388-99 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2013.08.005  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 149  |j 2013  |e 3  |b 28  |c 12  |h 388-99